Prognostic Influence of Galectin-1 in Gastric Adenocarcinoma
Authors:
- Cristina Díaz del ArcoCristina Díaz del Arco
- Lourdes Estrada MuñozLMLourdes Estrada Muñoz
- María de Los Ángeles Cerón NietoMNMaría de Los Ángeles Cerón Nieto
- Elena Molina RoldánERElena Molina Roldán
- María Jesús Fernández AceñeroMAMaría Jesús Fernández Aceñero
- Soledad García Gómez de Las HerasSHSoledad García Gómez de Las Heras
Open Access
- 7 July 2024
- journal article
- research article
- Published by MDPI AG in Biomedicines
- Vol. 12 (7) , 1508
Abstract
Galectin-1 (Gal-1), a member of the human lectin family, has garnered attention for its association with aggressive behavior in human tumors, prompting research into the development of targeted drugs. This study aims to assess the staining pattern and prognostic significance of Gal-1 immunohistochemical expression in a homogeneous cohort of Western patients with gastric cancer (GC). A total of 149 cases were included and tissue microarrays were constructed. Stromal Gal-1 expression was observed to some extent in most tumors, displaying a cytoplasmic pattern. Cases with stromal Gal-1 overexpression showed significantly more necrosis, lymphovascular invasion, advanced pTNM stages, recurrences, and cancer-related deaths. Epithelial Gal-1 expression was present in 63.8% of the cases, primarily exhibiting a cytoplasmic pattern, and its overexpression was significantly associated with lymphovascular invasion, peritumoral lymphocytic infiltration, and tumor-related death. Kaplan/Meier curves for cancer-specific survival (CSS) revealed a significantly worse prognosis for patients with tumors exhibiting stromal or epithelial Gal-1 overexpression. Furthermore, stromal Gal-1 expression stratified stage III patients into distinct prognostic subgroups. In a multivariable analysis, increased stromal Gal-1 expression emerged as an independent prognostic factor for CSS. These findings underscore the prognostic relevance of Gal-1 and suggest its potential as a target for drug development in Western patients with GC.Keywords
This publication has 93 references indexed in Scilit:
- Pooling analysis reveals that galectin‐1 is a reliable prognostic biomarker in various cancersJournal of Cellular Physiology, 2019
- Key regulators of galectin–glycan interactionsProteomics, 2016
- Cancer Incidence in Five Continents: Inclusion criteria, highlights from Volume X and the global status of cancer registrationInternational Journal of Cancer, 2015
- High expressions of galectin-1 and VEGF are associated with poor prognosis in gastric cancer patientsTumor Biology, 2013
- Alteration of galectin-1 during tumorigenesis of Opisthorchis viverrini infection-induced cholangiocarcinoma and its correlation with clinicopathologyTumor Biology, 2012
- Neuroblastoma triggers an immunoevasive program involving galectin‐1‐dependent modulation of T cell and dendritic cell compartmentsInternational Journal of Cancer, 2011
- The role of galectins in colorectal cancer progressionInternational Journal of Cancer, 2011
- CD24 and Galectin-1 Expressions in Gastric Adenocarcinoma and Clinicopathologic SignificancePathology and Oncology Research, 2010
- Galectin‐1 functions as a Th2 cytokine that selectively induces Th1 apoptosis and promotes Th2 functionEuropean Journal of Immunology, 2008
- Galectin-1 is highly expressed in human gliomas with relevance for modulation of invasion of tumor astrocytes into the brain parenchymaGlia, 2001